Novartis drops elinogrel outright
This article was originally published in Scrip
Executive Summary
Novartis has dealt another blow to its late-stage antiplatelet candidate elinogrel under cover of a major restructuring announcement. While announcing swingeing cuts to its US primary care sales force (scripintelligence.com, 13 January 2012), Novartis has also dropped elinogrel, once tipped as a blockbuster but quietly refocused in the pipeline last year.